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Microemulsions (MEs) were designed by an innovative rational development, characterized, and used to load up to 20mM of
Tamoxifen citrate (TMX). They were made with acceptable and well-characterized excipients for all the routes of administration.
Some of their properties, such as nanometric mean size and long stability shelf life, make them interesting drug delivery systems.
The results obtained after the in vitro inhibition of estradiol-induced proliferation in MCF-7 breast cancer cells demonstrated a
signiﬁcant eﬀect in cell growth. A decreasing of at least 90% in viable cells was shown after the incubation with MEs containing
20mM of TMX. Besides, two compositions which loaded 10mM of drug showed a cytotoxic eﬀect higher than 70%. These results
encouragetheevaluation ofalternativeprotocolsforthisdrugadministration,notonlyforestrogen receptor(ER)positivetumors,
but also for ER negative.
1.Introduction
One of the major problems facing cancer therapy is adminis-
tering the required therapeutic concentration of the drug at
the tumor site for the desired period of time. Targeted drug
delivery to solid tumors is necessary in order to achieve opti-
mum therapeutic outcomes. It would, therefore, be desirable
to develop chemotherapeutics that can either passively or
actively target cancerous cells. Passive targeting exploits the
characteristicfeaturesoftumorbiologythatallownanocarri-
ers to accumulate in the tumor by the enhanced permeability
and retention (EPR) eﬀect [1] .W h e r e a sf r e ed r u g sm a y
diﬀuse nonspeciﬁcally, a nanocarrier can extravasate into
the tumor tissues via the leaky vessels by the EPR eﬀect.
The dysfunctional lymphatic drainage in tumors retains the
accumulated nanocarriers. Particles with diameter <200nm
resulted in the most eﬀective ones [2, 3].
Microemulsions (MEs) are extensively studied nanocar-
riers; they are deﬁned as a system of water, oil, and amphi-
philewhichisasingleopticallyisotropicandthermodynami-
cally stable liquid solution. Their structure consists in micro-
domains of lipids or water stabilized by an interfacial ﬁlm of
surfactant and cosurfactant molecules. They can be classiﬁed
as oil in water (o/w) or water in oil (w/o) and the droplet
size is lower than 150 nanometers. They present a number
of advantages as drug delivery system, such as the ability
to solubilize hydrophobic drugs, spontaneous assemble,
long-term physical stability, and ease of manufacturing
[4]. They presented successful results for all administration
routes. There have also been of an increasing interest for
theiradministrationviatheparenteralroute[5,6],duetothe
number of acceptable excipients available nowadays [7, 8].
Tamoxifen citrate (TMX) (Figure 1), is an antiestrogen,
nonsteroidal derivative of triphenylethylene with poor water
solubility [9], that is widely used in hormone therapy
and breast cancer prevention even in an advanced stage.
Its use is especially indicated for postmenopausal women
who have estrogen-receptor- (ER-) positive breast cancer.
It is an estradiol competitive inhibitor for the estrogen
receptor. It inhibits proliferation by arresting the cell cycle2 Journal of Drug Delivery
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Figure 1: Chemical structure of tamoxifen citrate.
and induces breast cancer cells apoptosis [6, 10, 11]. It is also
thought to induce a tumoricidal eﬀect on estrogen receptor-
negativecellsbyincreasingthesecretionofinhibitorygrowth
factors. Recent reports have shown that TMX may possess
antiangiogenic activity through its antiestrogenic eﬀects [1].
TMX is administered by oral route in dose ranges from
20 to 40mg a day, but up to 200mg a day has been reported
[12]. Regarding pharmacokinetics, its oral bioavailability is
aﬀected by the ﬁrst pass eﬀect and is a substrate for some
protein families that mediate toxic compounds eﬄux outside
the organism [13]; it also presents vulnerability to enzymatic
degradation in both intestine and liver. Following long-term
therapy, TMX has some major side eﬀects, including higher
incidence of endometrial cancer, liver cancer, thromboem-
bolic disorders, and development of drug resistance [1].
To address the challenges of targeting tumors with nano-
technology, it is necessary to combine the rational design of
nanocarriers with the fundamental understanding of tumor
biology. It is to remark that an increasing number of na-
novectors are currently being tested for breast cancer treat-
ment, including liposomes and albumin-bound paclitaxel as
examples [14].
Because of the above-mentioned reasons, TMX repre-
sents a promising lipophilic model drug either for oral or
parenteral administration using MEs as passive targeting
drug delivery system. Therefore, an alternative protocol for
oral, IM, or IV administration in breast cancer or in ER-
negative tumors would be evaluated taking advantage of ME
properties [15].
The aim of the present work was to design and char-
acterize o/w MEs composed by pharmaceutically accepted
excipientsforTMXdelivery.Theywouldbefurtherproposed
for alternative protocols of oral or parenteral administration.
The biological behavior of the selected compositions for
passive targeting drug delivery was also evaluated in MCF-
7 human breast cancer cell line.
2.MaterialsandMethods
2.1. Material. Phosphatidylcholine (PC, Phospholipon
90NG) was purchased from Phospholipid, Germany; Pol-
yoxyethylene Sorbitan Monooleate (Polysorbate 80, PS 80)
was from Fisher Chemicals, NJ, USA; Tamoxifen citrate
was from Saporiti S.A., Buenos Aires, Argentina; ethanol
w a sb o u g h ta tJ .T .B a k e r ,U S A ;C a p m u lM C ML( g l y c e r o l
monocaprylocaprate) and Captex 355 (caprylic/capric Tri-
glyceride) were purchased from Abitec, Columbus, USA.
Estradiol was from Sigma Aldrich. St. Louis, MO, USA.
Imwitor 408 (propylene glycol caprylate) and Myiglyol 840
(propylene glycol dicaprylate/dicaprate) were from Sasol,
Witten, Germany. Oleic acid and Isopropyl mirystate were
from Merck, Germany. Propylene-glycol and polyethylene
glycol400wereboughtatBASF,NJ,USA.LabraﬁlM1944CS
(oleoyl macrogolglycerides (polyoxylglycerides) and Tran-
scutol P (diethylene glycol monoethyl ether) were purchased
from Gatefoss´ e, France. All reagents were of analytical grade.
Distilled water was obtained from a Milli-Q equipment.
2.2. Preliminary Solubility Evaluation for the Screening of
Components. PS 80 was selected as surfactant model because
it is listed as a generally recognized as safe (GRAS) excipient.
In addition, it is extensively used for diﬀerent ways of
administration, including the parenteral route [16], and for
microemulsions’ preparation [8].
ThesolubilityofTMXinanumberofexcipientswasesti-
mated. They were Isopropyl myristate (IPM), Mygliol 840,
Captex 355, Oleic acid, Imwitor 408, phosphatidylcholine
(PC) and Capmul MCM L. PC is solid at room temperature,
so a suspension was prepared (being 16% m/v the maximum
concentration tested). These oils are widely used as no polar
p h a s e sf o rM Ef o r m u l a t i o n[ 17, 18]. PC has also been used
for the formulation of parenteral MEs [19].
Regarding cosurfactants, ﬁve compounds were tested:
Ethanol, Polyethilenglycol 400 (PEG 400), Transcutol P,
Labraﬁl 1944 CS, and Propylenglycol (PG). All of them are
included in the FDA inactive ingredients guide.
To determine the drug solubility of TMX in excipients,
drug in excess was added until turbidity was reached. Then,
the samples were left to equilibrate using a Rotating Bottle
apparatus (Varian, USA) at 5RPM. If the solution was clear
after rotation for a short time, a more active compound
was added. Otherwise, the sample was left to equilibrate
for 72 hours and it was, then, ﬁltered using 0.45µmP V D F
membranes (Pall life sciences, USA). The ﬁltered sample was
analyzed by HPLC.
Quantitative determinations of TMX were performed
using a Shimadzu Class VP HPLC. The chromatographic
conditions were: column Zorbax Eclipse XDB Phenyl with
detection at 254nm; temperature was ﬁxed at 35◦C. The
mobile phase was constituted by methanol (1000mL),
water (320mL), acetic acid glacial (2mL), octansulphonate
(1.08g), and triethylamine (1mL).
These same conditions were also used for the determi-
nation of solubilizing capacity shown by formulations. All
experiments with TMX were carried out using amber glass
material due to drug photosensitivity.
2.3. Preliminary Cytotoxicity Assay. Although nonionic sur-
factants are considered less toxic than ionic surfactants, they
are often reported as responsible for a number of adverse
eﬀects[20].Thisisthemainissuethatpharmaceuticaldesign
has to overcome when formulating MEs, because high levels
of surfactants are sometimes needed.Journal of Drug Delivery 3
To assess the extent in which PS 80 could aﬀect cell
viability, a cytotoxicity assay using diﬀerent concentrations
was performed (5, 10, 20, and 25% m/v). The ﬁve co-
surfactants in solutions of 35% m/v and the seven lipids in
suspensions of 4% and 16% m/v were also evaluated.
For cytotoxicity studies, cells were seeded in clear 96-well
plates (Corning Costar, Fisher Scientiﬁc, USA) at a density
of 10,000 cells/well. After 24 hours, 5µL of the samples were
added in 200µL of medium. Cells were incubated at 37◦C
for 48 hours in a 5% CO2 atmosphere. Finally, the amount
of viable cells was determined using CellTiter 96 AQueous
Nonradioactive Cell Proliferation Assay (MTS), Promega.
2.4. Pseudoternary Phase Diagram Construction. Based on
solubility and preliminary cytotoxicity results, excipients
were selected to perform ME region screening. Diﬀerent
amounts of PS 80 and each one of the selected co-surfactants
and oil phases were mixed using magnetic stirrer during
10 minutes. Then, water was added and samples were left
to equilibrate using a thermal bath at 37◦C( V a r i a n ,U S A )
for 1 hour. The adopted criteria used for considering a
formulation as an ME was based on the visual analysis of the
compositions searching for clear, single-phase, isotropic and
low-viscous systems.
2.5. Screening and Optimization of MEs. Once the screening
was ﬁnished, a number of compositions were selected on
basis of noncytotoxic eﬀect of their components and also
on a high TMX solubilizing capacity. After that they were
evaluated for MCF-7 cells’ survival as described above.
2.6. Preparation of TMX-Loaded MEs. TMX-loaded MEs
were prepared by weighing appropriate amounts of PS 80,
the co-surfactant, and oil phase selected according with
previous adopted criteria; gentle magnetic stirring during 10
minutes at room temperature was applied so as to obtain
homogenous samples, which were left to equilibrate using
a thermal bath at 37◦C( V a r i a n ,U S A )f o r1h o u r .N e x t ,
three diﬀerent amounts of TMX were added and dissolved
with magnetic stirring. Finally, the corresponding amount of
water for each one of the selected compositions was added
under agitation at room temperature.
2.7. Physicochemical Characterization of TMX-Loaded MEs.
Density was measured using a Mettler Toledo 30 px. Formu-
lation of pH was determined with a pHmeter Mettler Toledo
seven easy. Conductivity was assessed using an Accumet
research AR20 at 25◦C; for rheological measurements a
Brookﬁeld DV-III Ultra at 25◦C was used. Polarization
microscopy was performed using an Olympus BH micro-
scope [21].
Droplet size was analyzed with a Nanozetasizer ZS, Mal-
vern Instruments, UK. Samples were not diluted to carry out
the measurements and assays were performed at 25◦C. The
polydispersity index indicates the size distribution within
a ME population. The z potential of the formulations was
determined using the same equipment (Nanozetasizer ZS,
Malvern Instruments, UK). Samples of the formulation were
placed in the electrophoretic cell, where an electric ﬁeld of
about 15V/cm was applied. The electrophoretic mobility
measured was converted into z potential using the Smolu-
chowski equation.
The morphology of MEs was studied using transmission
electron microscopy (TEM). The MEs were ﬁrst diluted in
water (1:40), a sample drop was placed onto a grid covered
with Formvar ﬁlm and the excess was drawn oﬀ with a ﬁlter
paper.Samplesweresubsequentlystainedwithuranylacetate
solution for 30s. Samples were ﬁnally dried in a closed
container with silica gel and analyzed. The droplet diameter
was estimated using a calibrated scale.
ChemicalstabilitywasperformedusingtheHPLCequip-
ment described for solubility assays (Shimadzu Class VP
HPLC), and the chromatographic conditions were also the
same. For short time stability studies, samples were left on
the bench at room temperature for a month and, then,
were reanalyzed. Direct observation of the formulations was
used to evaluate drug precipitation or other physical change
during the evaluation period.
The objective of thermodynamic stability is to evaluate
the phase separation and eﬀect of temperature variation on
MEs formulation. All the MEs prepared were centrifuged
(Eppendorf Centrifuge 5810) at 15,000rpm for 15min,
and then they were observed visually for phase separation.
Formulations that did not show any sign of phase separation
after centrifugation were subjected to freeze thaw cycle. In
af r e e z et h a ws t u d y ,T M XM E sw e r ee v a l u a t e df o rt w of r e e z e
thawcyclesbetween(−20◦Cand+25◦C)withstorageateach
temperature for not less than 4h [22].
2.8. Cell Culture Conditions. MCF-7 human breast cancer
cell line was obtained from the American Type Culture
Collection (ATCC) (Rockville, MD, USA). Cells were main-
tained in Dulbecco’s minimum essential medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 50µg/mL
gentamycine (Invitrogen Argentina), and 2mM L-glutamine
(InvitrogenArgentina). Cells wereculturedin 75cm2 culture
ﬂasks at 37◦C in a humidiﬁed atmosphere of 5% CO2.
2.9. Cytotoxicity and In Vitro Performance of the Selected
TMX-Loaded MEs. For in vitro performance studies, cells
were seeded in 96-well plates at a density of 5,000 cells/well.
After 24 hours, medium was replaced by phenol-red-free
media containing 2mM L-glutamine for 24 hours. To
analyze eﬀects of selected TMX-loaded formulations, cells
were subsequently incubated with estradiol 10nM and the
TMX-loaded MEs; in parallel, a TMX suspension containing
10mM of drug in presence and in absence of estradiol was
also evaluated. Cells were incubated further for 48 hours and
then cell viability was assessed by the cell proliferation assay
(MTS).
2.10. Statistical Analysis. Statistical calculations were per-
formed with the GraphPad InStat statistical package for
Windows. Data shown in tables and ﬁgures of in vitro prop-
erties evaluation represent mean of three determinations
± standard deviation (SD). Statistical signiﬁcance of the4 Journal of Drug Delivery
0
5
10
15
20
25
P
h
o
s
p
h
a
t
i
d
i
l
c
h
o
l
i
n
e
1
6
%
C
a
p
m
u
l
M
C
M
 
L
I
s
o
p
r
o
p
y
l
m
y
r
i
s
t
a
t
e
O
l
e
i
c
a
c
i
d
C
a
p
t
e
x
3
5
5
M
y
g
l
i
o
l
8
4
0
I
m
w
i
t
o
r
4
0
8
S
o
l
u
b
i
l
i
t
y
 
(
m
g
/
g
r
)
Lipids
(a)
0
2
4
6
8
10
12
14
16
18
T
w
e
e
n
8
0
E
t
h
a
n
o
l
L
a
b
r
a
ﬁ
l
P
E
G
4
0
0
T
r
a
n
s
c
u
t
o
l
P
r
o
p
y
l
e
n
g
l
y
c
o
l
S
o
l
u
b
i
l
i
t
y
 
(
m
g
/
g
r
)
(b)
Figure 2:(a)SolubilityofTamoxifencitrateinoilphases(expressed
in mg/g). Each bar represents the mean of three samples ± SD. (b)
Solubility of Tamoxifen Citrate in Polysorbate 80 and cosurfactants
(expressed in mg/g). Each bar represents the mean of three samples
± SD.
diﬀerences between the groups was calculated by the Tukey-
Kramer multiple comparison test and probability value
of P smaller than 0.05 indicated a statistically signiﬁcant
diﬀerence.
3. Results andDiscussion
3.1. Preliminary Solubility Evaluation. TMX resulted almost
insoluble in IPM, Mygliol 840, Captex 355, Oleic acid,
and Imwitor 408 and showed solubility near 20mg/g in
the PC suspension and in Capmul MCM L (Figure 2(a)).
Therefore,onlyPCandCapmulMCMLwereselectedforthe
forthcoming screening. The selection of the oily phase is very
important because the drug solubility in the formulation
depends mainly on it [23, 24]. So, this property results,
fundamental in the search for high solubilizing capacity
systems.
Lipid solubility values found in this work are in accord-
ancewithpreviousstudiesandsigniﬁcantlyhighercompared
to other lipids not considered in this study [25]. They also
were signiﬁcantly higher than TMX solubility in water
(≈20mg/mL and ≈0.4µg/mL, resp.). Furthermore, the high
solubility in PC is in accordance with previous works [26],
which stated that active compounds with an intermediate
lipophilicity (Log P of 4.0 and above, being 7.9 the value
of the Tamoxifen) have a high tendency to be solubilized by
phospholipids.
Solubility of TMX in the ﬁve co-surfactants and in PS
80 is depicted in Figure 2(b). The highest solubilizing ca-
pacity was achieved with PG and ethanol; therefore, both
compounds were selected to act as coemulsiﬁers in the forth-
comingMEscreening.However,TMXshowedaconsiderable
solubility in PEG 400 and Transcutol P,b u ti tr e s u l t e d
signiﬁcantly lower than the selected compounds (P<0.05).
Finally, Labraﬁl 1944 CS was discarded because it was the co-
surfactant with the lowest drug solubilizing capacity.
Solubility of TMX in PS 80 was around 5mg/g; however,
it is expected that these results slightly impact on the ﬁnal
therapeutic agent solubilization. The most important factor
that contributes to the ﬁnal ME solubilizing capacity in
poorly water soluble drugs is the solubility in the lipid
internal phase [26].
3.2. Preliminary Cytotoxicity Study. In order to avoid inter-
ference when testing selected vehicles for in vitro perfor-
mance, a preliminary cytotoxicity experiment on the MCF-7
cancer cell line was performed.
As it can be observed in Figure 3(a), only samples con-
taining 5% m/v of PS 80 exhibited low cytotoxicity; higher
concentrations than 5% m/v showed a percentage of cell
viability after treatment lower than 50%. Therefore, it can
be concluded that formulations containing PS 80 at concen-
trations above 5% would be toxic to the cells. Because of
it, false-positive results could be addressed when evaluating
their in vitro performance. As a result of the preliminary
surfactant cytotoxicity experiments and in order to avoid
excipient related eﬀects on the cells, ﬁnal formulations have
been diluted prior to their in vitro performance evaluation.
Oleic acid was the only no polar phase associated with cyto-
toxicity eﬀect at both assayed concentrations (Figure 3(b)).
Labraﬁl CS was the only cosurfactant which showed that
inconvenience.
3.3. Screening and Optimization of MEs. Based on solu-
bility and cytotoxicity results, the following excipients were
selected to perform the preliminary microemulsion screen-
ing: PS 80 as surfactant, ethanol, and PG as co-surfactants
and PC and Capmul MCM L as the oil phases.
Once the screening was ﬁnished, a number of com-
positions which resulted to be isotropic were selected and
are shown in Table 1. The selection included compositions
with a relative proportion of PS 80 lower than 20%, relative
concentrations of each one of the oil phases between 8 and
16%;theleveloftheco-surfactantswasﬁxedin25%.Noneof
these compositions containing PG as cosurfactant, matched
the adopted criterion for considering ME system and they
were discarded for the next step of selection.
In relation to Capmul MCM L, promising results were
observed in agreement with other authors; as it has beenJournal of Drug Delivery 5
Table 1: Composition of the selected microemulsions after the screening of excipients.
Formula Polysorbate 80 (%) PC (%) Capmul MCM L Propylene glycol (%) Ethanol (%) Water (%)
1 20 8 25 47
22 0 1 2 2 5 4 3
32 0 1 6 2 5 3 9
4 15 8 25 52
51 5 1 2 2 5 4 8
6 20 8 25 47
72 0 1 2 2 5 4 3
82 0 1 6 2 5 3 9
9 15 8 25 52
10 15 12 25 48
11 20 8 25 47
12 20 12 25 43
13 20 16 25 39
14 15 8 25 52
15 15 12 25 48
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Figure 3: (a) Cell viability of MCF-7 breast cancer cells incubated
at 37◦C for 48hrs with Polysorbate 80 at 25, 20, 10, and 5% m/v,
respectively. Each bar represents the mean of three samples ± SD.
(b) Cell viability of MCF-7 breast cancer cells incubated at 37◦Cf o r
48hrs with suspensions of 4% and 16% of each one of the selected
lipids. Each bar represents the mean of three samples ± SD.
recorded medium chain monoglycerides are known for their
ease of emulsiﬁcation when compared to ﬁxed oils or long-
chain fatty acids [5, 18]. They also exhibit good solubilizing
capacity. However, this oil phase could not be forthcoming
evaluated in MEs’ selection because of the high cytotoxicity
exhibited in cell cultures. Formulations containing Capmul
MCM L as oil phase were highly cytotoxic even though they
were diluted to avoid surfactant toxicity and that the lipid
alone did not show that property (Figures 4(a) and 4(b)). In
this case, cytotoxicity may be due to the eﬀect of the lipid on
cells when delivered by ME. For this reason, MEs containing
Capmul MCM L were discarded for the in vitro inhibition
of proliferation experiments and their pseudoternary phase
diagrams are not shown.
At this stage of the work, only MEs containing PC, etha-
nol, and PS 80 were selected. For their pseudoternary phase
diagrams construction, two diﬀerent surfactant/co sur-
factant ratios: 0.8 and 0.6 were considered (Figures 5(a) and
5(b)). Outside the isotropic systems areas, coarse emulsions
or gel-like structures were found for both studied surfac-
tant/cosurfactant ratios. MEs were found down to a water
concentration of 5% in both cases and up to 75% for the
systems containing a higher surfactant level (0.8 ratio) and
65% for the one with lower surfactant level (0.6 ratio).
Therefore, the higher level of surfactant did not signiﬁcantly
aﬀect the total area covered by isotropic systems in the
pseudoternary diagrams. After this, the study of ME region
was carried out again with the formulations containing
4mM of drug, so as to evaluate if there were signiﬁcant
changesin ME regions. No signiﬁcant changesin ME regions
were observed in both Pseudoternary phase diagram using
MEs containing 4mM of TMX.
This way of research, in which cytotoxicity evaluation is
done during the pharmaceutical development process, may
result at last, in biological ﬁndings more representative; and6 Journal of Drug Delivery
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Figure 4: (a) Cell viability of MCF-7 breast cancer cells incubated
at37◦Cfor48hrswithselected microemulsionsN◦ 1t oN ◦ 5,aftera
dilution (1:5) and without dilution. Each bar represents the mean
of three samples ± SD. (b) Cell viability of MCF-7 breast cancer
cells incubated at 37◦C for 48hrs with selected microemulsions N◦
6t oN ◦ 15 after 1:5 dilution. Each bar represents the mean of three
samples ± SD.
additionally in a shorter period of time. It is remarkable
that Cavalli et al. have recently reported that sometimes the
results are partially aﬀected by the conditions of culture
medium, as the use of Dimethyl sulfoxide (DMSO) in
cytotoxicity assays, for example [27].
3.4. Preparation and Solubility Evaluation of Selected MEs
Containing TMX. Results are shown in Figure 6 and as
it can be observed, there is a synergic eﬀect regarding
drug solubility in the MEs compared to the solubility in
the isolated excipients. This means that, in some cases,
the diﬀerence observed for solubilizing capacity is tenfold
higher.
Taking into account the composition of the MEs, the
solubility seems to increase with the raise in the lipid phase
content. Thus, the higher the surfactant percentage for
the same lipid level, the higher the solubility in the ME.
Considering TMX water solubility (≈0.4µg/mL) [28–30],
these systems represent an improvement of around 150000
fold for vehicle 4, which exhibited a solubility of 60mg/g.
3.5. Physicochemical Characterization. A signiﬁcant lowering
eﬀect of approximately 1.5 points in pH values was observed
when TMX was added. Conductivity values obtained for the
selected compositions correspond to those of o/w MEs [31,
32].
The low viscosity values are representative for MEs
(Table 2). The diﬀerences observed for viscosity values might
be the result of the interaction between ME droplets in
oil/watersystems.ItisexpectedthatPS80hydrophilicchains
are strongly hydrated and connected with hydrogen bonds;
this allows the interaction between the droplets, thus raising
the viscosity values [33]. It is also to remark that the higher
PC concentrations in the compositions, the higher viscosity
was observed.
All selected formulations were nonbirefringent when
analyzed with the polarized microscope, conﬁrming their
isotropy. It was concluded that MEs were not electrically
charged (z potential equal to 0mV) due to their ionic char-
acteristics and dipolar attributes.
Since ME formation process is generally a random stir-
ring process; the resulting delivery system may result in a
polydispersed system in which diﬀerent droplet sizes can
coexist. This information is extremely valuable in practice
because both stability and viscosity depend on the drop
size distribution [34]. The later in vivo or in vitro behavior
depends on this property as well [35]. Results shown in
Table 3 are in the typical range for a ME composition with
a narrow range of polydispersion as the polydispersity index
(PDI) shown [7]. TEM images also conﬁrmed this size
distribution (Figure 7)f o rb l a n kM EN ◦ 2. The addition
of TMX did not signiﬁcantly change droplet size of for-
mulations comparing with empty ones, even at the highest
TMX (20mM). This is an interesting advantage for the
selected compositions, because the loading of a lipophilic
active compound could result in an increase in the droplet
size and, eventually, could compromise the system physical
stability [35].
A short stability testing was carried out with selected
formulations. For this purpose, TMX 10mM was loaded
in order to achieve a ﬁnal concentration of approximately
5.10–4M in the culture media as the higher dose, accord-
ing to literature data [36]. Results demonstrated that all
formulations showed a 100 ± 2% of the initial content
after a month of observation. Obtained values conﬁrm
the total solubilization of the drug and absence of rapid
degradation (data not shown). Regarding physicochemical
values, no signiﬁcant changes in the values measured at
the beginning of the study were obtained after the studied
period. No precipitation or change in appearance was
observedbydirectvisualobservation.NoneoftheﬁfteenME
formulations has shown any sign of in-stabilization during
the thermodynamic stability tests carried out.
3.6. In Vitro Performance of Selected MEs. As a preliminary
experiment, the ﬁve empty MEs were cultured to assess
if they have any eﬀect on cell proliferation in presence of
10nM of estradiol. Two controls were also included: one
addingestradiol(10nM)tothecellsinordertodetermineits
proliferationeﬀectandtheothercontainingonlythecells.AsJournal of Drug Delivery 7
Transparent systems region
Water PC
Polysorbate 80/ethanol = 0.8
(a)
Transparent systems region
Water PC
Polysorbate 80/ethanol = 0.6
(b)
Figure 5: Pseudoternary phase diagrams of the selected formulations (Ratios Polysorbate 80: ethanol 0.8 and 0.6, resp.).
Table 2: Physicochemical parameters measured in the selected microemulsions. Data are expressed as mean ± SD (n = 3).
Formula Viscosity (mPa·s)
Empty ME
pH
(Empty ME)
pH
(Loaded ME)
Conductivity (uS/cm)
Empty ME
Density (g/mL)
Empty ME
14 5 .7 ±1.86 .11 ±0.02 4.62 ±0.02 71.1 ±0.91 .00 ±0.01
25 9 .4 ±4.36 .09 ±0.01 4.62 ±0.02 40.7 ±1.10 .98 ±0.01
37 9 .3 ±7.75 .96 ±0.02 4.67 ±0.01 65.2 ±1.60 .99 ±0.01
42 1 .2 ±2.36 .15 ±0.02 4.54 ±0.01 42.6 ±0.80 .99 ±0.01
52 9 .9 ±2.26 .00 ±0.05 4.61 ±0.02 40.2 ±1.10 .97 ±0.01
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Figure 6: Solubility of Tamoxifen citrate in the selected vehicles.
Each bar represents the mean of three samples ± SD (standard
deviation for n = 3).
it is shown in Figure 8, none of the empty ME showed eﬀects
per se over the MCF-7 cell line; it can be observed, instead,
theproliferativeeﬀectofestradiolonMCF-7cellline.Results
conﬁrmed that the dilution adopted was not cytotoxic.
The ﬁve selected formulations were loaded with the
following TMX concentrations, 11mg/g (20mM), 5.5mg/g
(10mM)and2.2mg/g(4mM);itisimportanttoremarkthat
100 nm
0 0 2 8 4 6
Figure 7: TEM photograph of Formulation 2 (×100000; dilution
1:40).
the in vitro performance of selected MEs was carried out in a
culture media containing estradiol 10nM.
The percentage of cellular viability of MCF-7 cells fol-
lowing inoculation of the above-mentioned TMX concen-
trations is illustrated in Figure 8. There was a signiﬁcant
decrease in cell growth for all formulations containing the8 Journal of Drug Delivery
Table 3: Mean droplet size for selected empty and loaded microemulsions. PdI: polydispersity index.
Formula Droplet size (nm) Empty ME pdI Droplet size (nm) Loaded ME pdI
1 5.72 0.344 6.04 0.407
2 5.37 0.237 6.04 0.297
3 5.41 0.256 4.97 0.174
4 9.54 0.365 9.62 0.368
5 8.43 0.389 8.33 0.210
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Figure 8: Cell viability of MCF-7 breast cancer cells incubated with
empty microemulsions and formulations containing Tamoxifen
citrate in the following concentrations: 11mg/g (20mM), 5.5mg/g
(10mM), 2.2mg/g (4mM). Each bar represents the mean of three
samples ± SD.
highest concentration of TMX. The viable cell percentages
after treatment were around 30 to 40% in all cases, that is, at
least 90% less of viable cells than the empty compositions;
ME N◦ 4 was the one which shown the highest cytotoxic
eﬀect. The same behavior was shown by the formulations
1 and 4 with the intermediate concentration of drug; in
these cases the diﬀerences shown were 75% and 90%,
respectively.
Thiscytotoxiceﬀectwasnotobservedwhenformulations
N◦ 1, 3, and 5 were loaded with 4mM of TMX. But it is to
remark that both ME N◦ 2a n dM EN ◦ 4 showed a signif-
icant lower number in viable cells when loading this drug
concentration. Additionally, it is worth noting that formulas
1, 4, and 5 showed a dose dependent eﬀect. Formulations 2
and 3 did not show signiﬁcant diﬀerences between the eﬀect
exerted by 10mM and the 4mM TMX concentrations. The
TMX suspension was not able to signiﬁcantly decrease the
number of viable cells in any cell culture condition (data not
shown).
Even though TMX mechanism of action has not been
completely elicited, it was reported that it acts primarily
through estrogen receptors (ERs) by modulation of gene
expression that ﬁnally leads to cell cycle arrest. However,
it has been informed that at higher concentrations could
induce breast cancer cell apoptosis [36]. This is an ER
independent and nongenomic eﬀect; it was found in ER
negative breast cancer cells and other cell types such as
malignant gliomas, pancreatic carcinomas, and melanomas.
On the other hand, estradiol has an antiapoptotic inﬂuence
in both, ER positive and negative cells, in addition to its
proliferative eﬀect on ER positive cells; the antiapoptotic
eﬀect has also been reported in MCF-7 breast cancer cell line
[37].
From the results obtained in cell cultures, it might con-
clude that all the compositions containing 20mM of TMX
showed an important cytotoxic eﬀect. This phenomenon
would be related with the induction of cellular apoptosis
described above; the eﬀect was also observed in ME N◦ 1a n d
4 containing 10mM TMX.
The % of viable cells observed would indicate that seven
of the ﬁfteen assayed compositions were able to solubilize
an enough amount of TMX capable to show a modiﬁcation
in the apoptosis cellular induction. It is also interesting to
remark that this phenomenon is observed in presence of the
above demonstrated proliferative eﬀect of estradiol.
It can be concluded that formulations 1 and 4 had the
best in vitro performance because they were able to show
an important antiproliferative eﬀect even when they were
loading the intermediate dose.
Another interesting observation to point out is that
formulation 3 showed the highest percentage of cell viability
at any TMX concentration; this formula is the one which
has the highest PC (16%) concentration. Previous reports
showed that PC content is increased in cancer cells and have
an important role in their proliferation [38, 39]. So, it is
expected that this stimulation on cell proliferation can be
attributedtothelevelsofPC.Thisobservationandthemech-
anism described above suggest that the proposed MEs would
present a high cellular uptake; anyway, PC proliferation
eﬀect has to be considered in further pharmacotherapeutic
evaluation.
The obtained MEs are promising in the current state
of increasing interest for nanocarriers that can be used for
TMX delivery. For example, Chawla and Amiji, examined
biodegradable polymeric nanoparticles uptake and distri-
bution in MCF-7 breast cancer cell line. They compared
TMX intracellular concentration when delivered by the
nanoparticles and in solution, and they found that the
drug uptake from the nanoparticles followed a saturable
transport. Therefore, above certain concentration, TMX
intracellular concentration was much higher when delivered
by the solution [1]. On the contrary, MEs designed in this
work did not show signs of limited transport in none of
the selected drug concentrations. Besides, it is expected that
MEs can improve drug cellular uptake not even for a betterJournal of Drug Delivery 9
drug solubilizing capacity but also for the improvement
in biopharmaceutical parameters that have been extensively
described for them [4, 7, 8, 13, 15, 17, 18].
Al Haj et al. evaluated TMX-loaded solid lipid nanopar-
ticles for parenteral administration, and, though promising,
these systems required a sophisticated preparation method
because they were elaborated by high pressure homogeniza-
tion technique [40]. Instead of this, the ease of preparation is
a common ME characteristic.
Tagne et al. evaluated a nanoemulsion containing TMX
that has a signiﬁcantly better in vitro performance reducing
cell proliferation when compared to a TMX-loaded sus-
pension. However, they have used a concentration of TMX
equal to 3 × 10−5M for all the cell culture treatments,
while our MEs were able to solubilize more than 100-
fold higher of TMX [6]. These authors claimed for an
important cellular uptake because of the nanometric sizes of
the nanoemulsions. Similar results could be expected with
our formulations but the in vivo therapeutic parameters
would be improved because of the drug concentration
achieved.
Another important diﬀerence between both works is
the technique of preparation. They used a microﬂuidizer
processor which provides a resultant high shear rate by accel-
eratingtheproductthroughmicrochannelstoahighvelocity
for size reduction to the nanoscale range. They previously
prepared a suspension of TMX and then the mixture was
homogenized. On the contrary, MEs involve a spontaneous
process of formation for a deﬁned composition and the
selection of the composition is searched through a screening
of components. As a result of these two diﬀerent techniques
they found a negative z potential while we observed no
charges on the droplets’ layers. Another consequence was
that they obtained a bimodal distribution of mean droplet
sizes; on the contrary, we observed a more uniform dis-
tribution. In conclusion, the above-mentioned diﬀerences
are in relation with the fact that Tagne et al. have prepared
nanoemulsions, while our work deals on MEs; it is very clear
inliteraturethediﬀerencesbetweenthemindependentlythat
they could have similar compositions and mean droplet size
[4, 8, 41].
More recently, the electrospray technique was proposed
toproduceTMX-loadedpoly(amidoamine)-cholesterolcon-
jugate nanoparticles in powder form without any excipient
in a single step. Spite of this, the nanoparticles showed sizes
higher than 200nm and a drug loading of about 40% [27].
It is also necessary to remark that the cell culture
experiments were carried out with no reagent addition;
this is a very important issue because previous report [27,
42] found that MCF7 cells are highly sensitive towards
DMSO. Indeed, volumes equal to or higher than 2µL( 2 %
v/v) result in a cytotoxic eﬀect that partially overlaps the
one observed in cells treated with free TMX diluted in
DMSO. Therefore, this “background” cytotoxicity leads to
an overestimation of the free TMX activity. On the contrary,
every step done in this work during the development of the
experimental design was adjusted so as to strictly evaluate
the in vitro behavior showed by each one of the selected
compositions.
4. Conclusion
The present work describes a novel interdisciplinary rational
screening for a ME composition, its optimization, and
the corresponding in vitro performance evaluation on
MCF-7 breast cancer cell line. The development included
physicochemical properties evaluation and drug solubility
in selected formulations. The experimental design began
with the proposal of extensively studied excipients for the
screening, after that, the ﬁrst criterion adopted for excipient
selection was based on solubilizing capacity; then cytotoxic
was evaluated. The ﬁnal criterion of selection was the ability
to form MEs shown by each one of the excipients.
It is our opinion that this design layout allows a faster
optimization of MEs composition. The drug-loading capac-
ity was investigated using TMX, a poorly water soluble an-
tineoplastic drug, as an active compound model. Non-
adherence to oral medication is an increasingly recognized
concern in the care of cancer patients and considering that
every year, hundreds of thousands of women worldwide are
recommended to take TMX for 5 years; a diﬀerent protocol
of treatment would be evaluated. Not only other oral
administration protocol but also an IM or IV formulation
can ﬁnally be proposed after the in vivo experiments. In
addition, some other ER-negative cancers, which have also
shown to be sensitive to TMX may be further evaluated with
MEs’ containing diﬀerent pharmacological doses. Thus, a
more eﬃcient drug release proﬁle would potentially prevent
the development of cancer cell resistance.
Consequently, these MEs result in a promising alter-
native for further in vivo evaluation. Finally, Peer et al.
mentioned that for rapid and eﬀective clinical translation,
the nanocarriers should present some characteristics that
theseonesdoexhibit[2].Theyaremadewithbiocompatible,
well-characterized, and easily functionalized excipients; they
are both soluble and colloidal dosage forms under aqueous
conditions which are related to increased eﬀectiveness. And
they have a low rate of aggregation and a long shelf life. They
would also exhibit diﬀerential uptake eﬃciency in the target
cells over normal cells because they show passive targeting.
Acknowledgment
SupportforthesestudieswasprovidedbytheNationalAgen-
cy of Scientiﬁc and Technological Promotion (ANPCyT);
Ministry of Science, Technology and Productive Innovation,
Argentina, the University of Buenos Aires; the National
Science Research Council (CONICET).
References
[1] J. S. Chawla and M. M. Amiji, “Cellular uptake and concen-
trations of tamoxifen upon administration in poly(E-capro-
lactone) nanoparticles,” AAPS PharmSci, vol. 5, no. 1, article
E3, 2003.
[ 2 ] D .P e e r ,J .M .K a rp ,S .H o n g,O .C .F a r o k h z a d ,R .M a r ga l i t ,a n d
R. Langer, “Nanocarriers as an emerging platform for cancer
therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760,
2007.10 Journal of Drug Delivery
[3] E. Cukierman and D. R. Khan, “The beneﬁts and challenges
associated with the use of drug delivery systems in cancer
therapy,” Biochemical Pharmacology, vol. 80, no. 5, pp. 762–
770, 2010.
[4] M. J. Lawrence and G. D. Rees, “Microemulsion-based media
as novel drug delivery systems,” Advanced Drug Delivery
Reviews, vol. 45, no. 1, pp. 89–121, 2000.
[5] R. G. Strickley, “Solubilizing excipients in oral and injectable
formulations,” Pharmaceutical Research,v o l .2 1 ,n o .2 ,p p .
201–230, 2004.
[6] J. B. Tagne, S. Kakumanu, D. Ortiz, T. Shea, and R. J. Nicolosi,
“A nanoemulsion formulation of tamoxifen increases its
eﬃcacy in a breast cancer cell line,” Molecular Pharmaceutics,
vol. 5, no. 2, pp. 280–286, 2008.
[7] A. A. Date and M. S. Nagarsenker, “Parenteral microemul-
sions: an overview,” International Journal of Pharmaceutics,
vol. 355, no. 1-2, pp. 19–30, 2008.
[8] S. Gupta and S. P. Moulik, “Biocompatible microemulsions
and their prospective uses in drug delivery,” Journal of
Pharmaceutical Sciences, vol. 97, no. 1, pp. 22–45, 2008.
[9] S. Gao and J. Singh, “In vitro percutaneous absorption en-
hancementofalipophilicdrugtamoxifenbyterpenes,”Journal
of Controlled Release, vol. 51, no. 2-3, pp. 193–199, 1998.
[10] J. L. Jones, B. J. Daley, B. L. Enderson, J. R. Zhou, and M.
D. Karlstad, “Genistein inhibits tamoxifen eﬀects on cell pro-
liferation and cell cycle arrest in T47D breast cancer cells,”
American Surgeon, vol. 68, no. 6, pp. 575–577, 2002.
[11] R. L. Sutherland, R. E. Hall, and I. W. Taylor, “Cell prolifera-
tion kinetics of MCF-7 human mammary carcinoma cells in
culture and eﬀects of tamoxifen on exponentially growing and
plateau-phase cells,” Cancer Research, vol. 43, no. 9, pp. 3998–
4006, 1983.
[12] J. G. Hardman, L. E. Limbird, and A. G. Gilman, The Phar-
macologicalBasisofTherapeutics,M cGra w-Hill,N ewY ork,NY ,
USA, 10th edition, 2006.
[13] S. C. Shin, J. S. Choi, and X. Li, “Enhanced bioavailability
of tamoxifen after oral administration of tamoxifen with
quercetin in rats,” International Journal of Pharmaceutics, vol.
313, no. 1-2, pp. 144–149, 2006.
[14] T. Tanaka, P. Decuzzi, M. Cristofanilli et al., “Nanotechnology
forbreastcancertherapy,”BiomedicalMicrodevices,vol.11,no.
1, pp. 49–63, 2009.
[15] S. Kakumanu, J. B. Tagne, T. A. Wilson, and R. J. Nicolosi, “A
nanoemulsion formulation of dacarbazine reduces tumor size
in a xenograft mouse epidermoid carcinoma model compared
to dacarbazine suspension,” Nanomedicine,v o l .7 ,n o .3 ,p p .
277–283, 2011.
[16] R.Rowe,P.Sheskey,andM.Quinn,HandbookofPharmaceuti-
cal Excipients, Pharmaceutical Press, London, UK, 6th edition,
2010.
[17] C. W. Pouton, “Formulation of poorly water-soluble drugs for
oral administration: physicochemical and physiological issues
and the lipid formulation classiﬁcation system,” European
Journal of Pharmaceutical Sciences, vol. 29, no. 3-4, pp. 278–
287, 2006.
[18] A. A. Kale and V. B. Patravale, “Development and evaluation
of lorazepam microemulsions for parenteral delivery,” AAPS
PharmSciTech, vol. 9, no. 3, pp. 966–971, 2008.
[19] A. Spernath, A. Aserin, and N. Garti, “Fully dilutable
microemulsions embedded with phospholipids and stabilized
by short-chain organic acids and polyols,” Journal of Colloid
and Interface Science, vol. 299, no. 2, pp. 900–909, 2006.
[20] N. Gursoy, J. S. Garrigue, A. Razaﬁndratsita, G. Lambert, and
S. Benita, “Excipient eﬀects on in vitro cytotoxicity of a novel
paclitaxel self-emulsifying drug delivery system,” Journal of
Pharmaceutical Sciences, vol. 92, no. 12, pp. 2411–2418, 2003.
[21] F. Nielloud and G. Marti-Mestres, Pharmaceutical Emulsions
and Suspensions, Marcel Dekker, New York, NY, USA, 2000.
[22] A. K. Singh, A. Chaurasiya, A. Awasthi et al., “Oral bioavaila-
bility enhancement of exemestane from self-microemulsifying
drug delivery system (SMEDDS),” AAPS PharmSciTech, vol.
10, no. 3, pp. 906–916, 2009.
[23] A. Palamakula and M. A. Khan, “Evaluation of cytotoxicity
of oils used in coenzyme Q10 Self-Emulsifying Drug Delivery
Systems(SEDDS),”InternationalJournalofPharmaceutics,vol.
273, no. 1-2, pp. 63–73, 2004.
[24] C. J. H. Porter, C. W. Pouton, J. F. Cuine, and W. N. Charman,
“Enhancing intestinal drug solubilisation using lipid-based
deliverysystems,”AdvancedDrugDeliveryReviews,vol.60,no.
6, pp. 673–691, 2008.
[ 2 5 ]Y .S .R .E l n a g g a r ,M .A .E l - M a s s i k ,a n dO .Y .A b d a l l a h ,“ S e l f -
nanoemulsifying drug delivery systems of tamoxifen citrate:
design and optimization,” International Journal of Pharmaceu-
tics, vol. 380, no. 1-2, pp. 133–141, 2009.
[26] M. Sznitowska, E. A. Dabrowska, and S. Janicki, “Solubilizing
potential of submicron emulsions and aqueous dispersions of
lecithin,” International Journal of Pharmaceutics, vol. 246, no.
1-2, pp. 203–206, 2002.
[27] R. Cavalli, A. Bisazza, R. Bussano et al., “Poly(amidoamine)-
cholesterol conjugate nanoparticles obtained by electrospray-
ing as novel tamoxifen delivery system,” Journal of Drug Deliv-
ery, vol. 2011, Article ID 587604, 9 pages, 2011.
[28] G. R. De Lima, G. Facina, J. Y. Shida et al., “Eﬀects of low
dose tamoxifen on normal breast tissue from premenopausal
women,” European Journal of Cancer, vol. 39, no. 7, pp. 891–
898, 2003.
[29] G. Cavallaro, L. Maniscalco, M. Licciardi, and G. Giammona,
“Tamoxifen-loaded polymeric micelles: preparation, physico-
chemical characterization and in vitro evaluation studies,”
MacromolecularBioscience,vol.4,no.11,pp.1028–1038,2004.
[30] F. X. Hu, K. G. Neoh, and E. T. Kang, “Synthesis and in vitro
anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA
composite nanoparticles,” Biomaterials, vol. 27, no. 33, pp.
5725–5733, 2006.
[ 3 1 ]P .B o o n m e ,K .K r a u e l ,A .G r a f ,T .R a d e s ,a n dV .B .J u n y a -
prasert, “Characterization of microemulsion structures in the
pseudoternary phase diagram of isopropyl palmitate/water/
Brij 97:1-butanol,” AAPS PharmSciTech, vol. 7, no. 2, article
45, pp. E1–E6, 2006.
[32] W. Zhu, A. Yu, W. Wang, R. Dong, J. Wu, and G. Zhai, “For-
mulation design of microemulsion for dermal delivery of pen-
ciclovir,” International Journal of Pharmaceutics, vol. 360, no.
1-2, pp. 184–190, 2008.
[ 3 3 ]F .P o d l o g a r ,M .G a ˇ sperlin, M. Tomˇ siˇ c, A. Jamnik, and M. B.
Rogaˇ c, “Structural characterisation of water-Tween 40/Im-
witor 308-isopropyl myristate microemulsions using diﬀerent
experimental methods,” International Journal of Pharmaceu-
tics, vol. 276, no. 1-2, pp. 115–128, 2004.
[34] S. A. Charman, W. N. Charman, M. C. Rogge, T. D. Wilson,
F. J. Dutko, and C. W. Pouton, “Self-emulsifying drug deliv-
ery systems: formulation and biopharmaceutic evaluation
of an investigational lipophilic compound,” Pharmaceutical
Research, vol. 9, no. 1, pp. 87–93, 1992.
[35] B. D. Tarr and S. H. Yalkowsky, “Enhanced intestinal absorp-
tion of cyclosporin in rats through the reduction of emulsion
droplet size,” Pharmaceutical Research, vol. 6, no. 1, pp. 40–43,
1989.Journal of Drug Delivery 11
[36] H. K. Dhiman, A. R. Ray, and A. K. Panda, “Three-dimen-
sional chitosan scaﬀold-based MCF-7 cell culture for the de-
termination of the cytotoxicity of tamoxifen,” Biomaterials,
vol. 26, no. 9, pp. 979–986, 2005.
[37] A. Zheng, A. Kallio, and P. H¨ ark¨ onen, “Tamoxifen-induced
rapid death of MCF-7 breast cancer cells is mediated via
extracellularly signal-regulated kinase signaling and can be
abrogated by estrogen,” Endocrinology, vol. 148, no. 6, pp.
2764–2777, 2007.
[38] M. Ba˜ nez-Coronel, A. Ram´ ırez de Molina, A. Rodr´ ıguez-
Gonz´ alez et al., “Choline kinase alpha depletion selectively
kills tumoral cells,” Current Cancer Drug Targets, vol. 8, no.
8, pp. 709–719, 2008.
[39] S. Sinha Roy, S. Mukhopadhyay, S. Mukherjee, and S. K. Das,
“Breastcancer isassociated withanincreaseintheactivity and
expression of cholinephosphotransferase in rats,” Life Sciences,
vol. 83, no. 19-20, pp. 661–665, 2008.
[40] N. A. Al Haj, R. Abdullah, S. Ibrahim, and A. Bustamam,
“Tamoxifen drug loading solid lipid nanoparticles prepared
by hot high pressure homogenization techniques,” American
Journal of Pharmacology and Toxicology, vol. 3, no. 3, pp. 219–
224, 2008.
[41] P. Shah, D. Bhalodia, and P. Shelat, “Nanoemulsion: a
pharmaceutical review,” Systematic Reviews in Pharmacy, vol.
1, no. 1, pp. 24–32, 2010.
[42] M. Licciardi, G. Cavallaro, M. Di Stefano, G. Pitarresi, C. Fior-
ica, and G. Giammona, “New self-assembling polyaspartyl-
hydrazide copolymer micelles for anticancer drug delivery,”
International Journal of Pharmaceutics, vol. 396, no. 1-2, pp.
219–228, 2010.